Fosun Pharmaceuticals (600196.SH) subsidiary obtains exclusive license for T-MATE™ technology platform

Zhitongcaijing · 2d ago

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) announced that on September 23, 2026, the holding subsidiary Fuhong Hanlin signed a “Cooperation and License Agreement” with Amberstone. Fuhong Hanlin was awarded by Amberstone to research, develop, produce, and commercialize two cooperative products (i.e. T Cell Engager, TCE) products for agreed targets based on the T-MATE™ technology platform worldwide and in all fields of human use Exclusive license.

According to reports, the T-MATE ™ technology platform is Amberstone's proprietary tumor microenvironment activation technology platform. By regulating the activation state of TCE molecules in the tumor microenvironment and peripheral tissues, increasing its selective effect on tumor tissue and reducing potential effects on normal tissue, it is expected to improve the narrow treatment window and limited safety of traditional TCE products in solid tumor treatment. Fuhong Hanlin should pay Amberstone up to US$236 million in down payment, R&D expenses, development and regulatory milestones, and up to US$652 million in graded sales milestones for this cooperation. The purpose of this cooperation is to make full use of the technical advantages and R&D capabilities of the two partners in related fields, jointly promote research and development of new products in the field of cancer treatment, and continue to enrich the company's product pipeline in this field of treatment.